The risk for type 1 and type 2 diabetes from childhood into adulthood is increased in preterm-born individuals.
Women with higher serum SHBG had an increased risk for osteoporosis, osteopenia, and fracture.
Increased compliance with continuous positive airway pressure therapy may reduce the risk for the development of diabetic retinopathy in patients with type 2 diabetes who have obstructive sleep apnea.
Higher systolic blood pressure and decreased low-density lipoprotein are associated with increased risk for peripheral neuropathy in patients with type 2 diabetes.
Treatment with SGLT2 inhibitors empagliflozin and dapagliflozin may be associated with less decline in kidney function across different chronic kidney disease stages.
For patients with newly diagnosed type 2 diabetes, visit-to-visit HbA1c variability is associated with increased risks for cardiovascular disease and microvascular complications.
Sleep may be an important modifiable factor in disease management in patients with type 2 diabetes, especially variation in sleep duration.
Treatment with canagliflozin was associated with similar reductions in HbA1c compared with any dose of a GLP-1 receptor agonist, with better treatment adherence and lower annual costs.
Treatment with empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, was associated with reduced risk of hospitalization for heart failure when compared with use of dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide (GLP)-1 receptor agonists.
A hospital-based cohort study found sex heterogeneity in the severity of osteoarthritis symptoms in type 2 diabetes, and an association between insulin treatment and pain severity in men.